Press Releases

Over 70% of patients reach target with NovoMix® 30 in largest ever diabetes study (9 Jun 2008)

Dansk version
Read in PDF format

[San Francisco, USA] - New data from the IMPROVE™ study show that significant improvements in glycaemic (blood sugar) control can be achieved with premixed modern insulin, NovoMix® 30, in patients poorly controlled on other, or no previous pharmaceutical treatment. The results were announced over the weekend at the 68th annual meeting of the American Diabetes Association (ADA) in San Francisco.

IMPROVE™ is the largest ever observational study in diabetes involving nearly 58,000 patients from 11 countries and was designed to assess the safety and effectiveness of NovoMix® 30 in type 2 diabetes.

The study showed that on average, patients’ overall HbA1c levels (the key measure for diabetes control) dropped significantly – by 2.6 percentage points – after treatment with NovoMix® 30.1 While there was a large drop in HbA1c of 2.5 percentage points in patients who had not been previously treated with insulin2, an even greater improvement of 3.0 percentage points was seen in those who had previously been poorly controlled on other insulin regimens.3

Overall, a total of 71% of patients reached the HbA1c target level of less than or equal to 7%1 and this was achieved with a 70% reduction in patient-reported major hypoglycaemic events and no significant weight gain.1 These results also had a significant impact on quality of life – average score of patient satisfaction with treatment rose from 57.2 (out of 100) to 74.5 by the end of the study.4 

“While the number of people left with very high HbA1c levels before treatment with insulin is alarming, it is encouraging that treatment with NovoMix® 30 was able to bring them in good control in just six months,” said Professor Paul Valensi, head of the Department of Endocrinology-Diabetology-Nutrition at the Jean Verdier Hospital in France, and principal investigator of the IMPROVE™ study. “NovoMix® 30 is clearly an effective treatment option for poorly controlled diabetes patients.”

Despite the global burden of diabetes and its serious health consequences, many patients are either left untreated or on a treatment that is no longer effective, both of which can exacerbate complications and co-morbidities. The extent of ineffective glycaemic control is confirmed by the baseline data from IMPROVE™, with average HbA1c levels of 9.4% at the beginning of the study.5 As a result, many patients had macro- (27.5%) and microvascular (42.1%) complications when they were enrolled.5

The results presented at ADA were from a preliminary analysis of 17,313 patients from China, Japan, Poland, Italy, India and Russia, who had completed the study by November 2007. The final results from the full IMPROVETM study population will be available later in the year. 

NovoMix® 30 is used as a simple way to start insulin in many countries. The dose can easily be intensified as patients’ diabetes inevitably progresses. This is done simply and without changing treatment, therefore offering patients increased reassurance and control over their condition.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 26,300 employees in 80 countries, and markets its products in 179 countries. Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit novonordisk.com.

Further information:

Media:

Investors:

 

 

Outside North America:

Outside North America:

Elin K Hansen

Mads Veggerby Lausten

Tel: (+45) 4442 3450

Tel: (+45) 4443 7919

ekh@novonordisk.com 

mlau@novonordisk.com

 

 

 

Hans Rommer

 

Tel: (+45) 4442 4765

 

hrmm@novonordisk.com

 

 

In North America:

In North America:

An Phan

Christian Qvist Frandsen

Tel: (+1) 609 558 0420

Tel: (+1) 609 919 7937

anph@novonordisk.com

cqfr@novonordisk.com

 

References

1.      Shaban J, Hansen JB, Yang WY.  NovoMix® 30 (BIAsp 30) Improves Glycemic Control in Type 2 Diabetes: Results from the IMPROVE™ Study.  American Diabetes Association. 68th Scientific Sessions; 2008 June 7-10; San Francisco, CA. Abstract Number: 2108

2.      Gumprecht J, Hansen J, Borzi V. Improved Glycemic Control with NovoMix® 30 (BIAsp 30) in Insulin-naïve Patients with Type 2 Diabetes: Subgroup Analysis from the IMPROVE™ Study. American Diabetes Association. 68th Scientific Sessions; 2008 June 7-10; San Francisco, CA. Abstract Number: 2090

3.      Shah S, Ørskov C, Kawamori R. Switching to NovoMix® 30 (BIAsp 30) Improves Glycemic Control in Patients with Type 2 Diabetes Previously Treated with Insulin: Subgroup Analysis from the IMPROVE™ Study. American Diabetes Association. 68th Scientific Sessions; 2008 June 7-10; San Francisco, CA. Abstract Number: 2142

4.      Yang WY, Christensen T, Kawamori R. Patient Treatment Satisfaction Improves after Switching to NovoMix® 30 (BIAsp 30): the IMPROVE™ Study Data. American Diabetes Association. 68th Scientific Sessions; 2008 June 7-10; San Francisco, CA. Abstract Number: 2114

5.      Valensi P, Ørskov C, Shah S. Poor Glycemic Control at Baseline: Analyses from the IMPROVE™ Study. American Diabetes Association. 68th Scientific Sessions; 2008 June 7-10; San Francisco, CA. Abstract Number: 2250 

 

  •  
Search for Danish versions and earlier news releases:

Language
Year
Month
Type
Search for:

Search
  •  
  •  

Sign up for the latest news from Novo Nordisk

SMS/e-mail

Twitter

Facebook

RSS feeds

 
  •  
  •  
Pipeline
  •  
  •  
Click here to go to the download centre to download presenations, reports or magazines
  •